Author:
Warso M A,Richards J M,Mehta D,Christov K,Schaeffer C,Rae Bressler L,Yamada T,Majumdar D,Kennedy S A,Beattie C W,Das Gupta T K
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Alexandroff AB, Jackson AM, O'Donnell MA, James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353 (9165): 1689–1694
2. Anderson KC, Hannah AL, Pazdur R, Farrell AT (2007) A strategic framework for novel drug development in multiple myeloma. Br J Haematol 138 (2): 153–159
3. Andreeff M, Kojima K, Padmanabhan S, Strair R, Kirschbaum M, Maslak P, Hillmen P, O'Brien S, Samaniego F, Borthakur G, Konopleva M, Vassilev L, Nichols G (2010) A multi-center, open-label, phase i study of single agent RG7112, A first in class p53-MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas (CLL/SCLL). Blood (ASH Annual Meeting Abstracts) 116: 657
4. Arkenau HT, Olmos D, Ang JE, Barriuso J, Karavasilis V, Ashley S, de Bono J, Judson I, Kaye S (2008) 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer 44 (11): 1536–1540
5. Bizzarri AR, Santini S, Coppari E, Bucciantini M, Di Agostino S, Yamada T, Beattie CW, Cannistraro S (2011) Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy. Int J Nanomed 6: 3011–3019
Cited by
153 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献